3-[2-chloro-7-[(dimethylamino)methyl]naphthalen-1-yl]-4-[7-[2-(2-methoxyethoxy)ethoxy]-1H-indol-3-yl]pyrrole-2,5-dione;3-(1H-indol-3-yl)-4-(2-piperazin-1-ylquinazolin-4-yl)pyrrole-2,5-dione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 3-[2-chloro-7-[(dimethylamino)methyl]naphthalen-1-yl]-4-[7-[2-(2-methoxyethoxy)ethoxy]-1H-indol-3-yl]pyrrole-2,5-dione;3-(1H-indol-3-yl)-4-(2-piperazin-1-ylquinazolin-4-yl)pyrrole-2,5-dione
• 化学式: C54H50ClN9O7
• 分子量: 972.5
• InChiKey: ABNWCIBOIUSMTO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.73
• 重原子数：
  71
• 可旋转键数：
  14
• 环数：
  11.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  196
• 氢给体数：
  5
• 氢受体数：
  12

文献信息

• PHARMACEUTICAL COMBINATIONS
  申请人：Novartis AG

  公开号：EP2925366A1

  公开（公告）日：2015-10-07
• [EN] PHARMACEUTICAL COMBINATIONS<br/>[FR] COMBINAISONS PHARMACEUTIQUES
  申请人：NOVARTIS AG

  公开号：WO2014085381A1

  公开（公告）日：2014-06-05

  A pharmaceutical combination comprising (a) a protein kinase C (PKC) inhibitor compound, or a pharmaceutically acceptable salt thereof, and (b) at least one mitogen activated protein kinase (MEK) inhibitor or a pharmaceutically acceptable salt, and optionally a pharmaceutically acceptable carrier, for simultaneous, separate or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.